Format

Send to

Choose Destination
J Immunol. 2019 Oct 2. pii: ji1900807. doi: 10.4049/jimmunol.1900807. [Epub ahead of print]

The Tumor-Immune Response Is Not Compromised by Mesenchymal Stromal Cells in Humanized Mice.

Author information

1
Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec H3T 1C5, Canada.
2
Département de Pharmacologie et Physiologie, Faculté de Médecine, Université de Montréal, Montreal, Quebec H3T 1J4, Canada.
3
Direction de l'Innovation, Affaires Médicales et Innovation, Héma-Québec, Quebec G1V 5C3, Canada.
4
Centre Intégré Universitaire de Santé et de Services Sociaux, Centre-Sud-de-l'Île-de-Montréal, Montreal, Quebec H1T 2M4, Canada.
5
Département de Pédiatrie, Faculté de Médecine, Université de Montréal, Montreal, Quebec H3T 1J4, Canada; and.
6
Département de Microbiologie, Immunologie et Infectiologie, Faculté de Médecine, Université de Montréal, Montreal, Quebec H3T 1J4, Canada.
7
Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec H3T 1C5, Canada; c.beausejour@umontreal.ca.

Abstract

Therapeutic uses of mesenchymal stromal cells (MSCs) have emerged over the past decade. Yet, their effect on tumor growth remains highly debated, particularly in an immune competent environment. In this study, we wanted to investigate the impact of human umbilical cord-derived MSCs (hUC-MSCs) on tumor growth in humanized mice generated by the human adoptive transfer of PBMCs or the cotransplantation of hematopoietic stem cells and human thymic tissue (human BLT [Hu-BLT]). Our results showed that the growth and immune rejection of engineered human fibroblastic tumors was not altered by the injection of hUC-MSCs in immune-deficient or humanized mice, respectively. This was observed whether tumor cells were injected s.c. or i.v. and independently of the injection route of the hUC-MSCs. Moreover, only in Hu-BLT mice did hUC-MSCs have some effects on the tumor-immune infiltrate, yet without altering tumor growth. These results demonstrate that hUC-MSCs do not promote fibroblastic tumor growth and neither do they prevent tumor infiltration and rejection by immune cells in humanized mice.

PMID:
31578272
DOI:
10.4049/jimmunol.1900807

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center